• Cancer Imaging Program Fellowships

    The Cancer Imaging Program (CIP) Fellowship at Dana-Farber Cancer Institute provides extensive experience in body imaging, including MRI, CT, PET-CT, and US in adult patients with cancer.

    Cancer Imaging Program Fellowship

    Equipment and resources

    State-of-the-art equipment includes 64-slice CT, 1.5-T and 3-T MRI, PET-CT, digital radiography, US and gamma camera systems. Dana-Farber also serves as a core imaging analysis laboratory for imaging studies performed in the context of local, national, and global clinical trials.

    Rotation overview
    • The CIP fellow rotates in CT, MRI, US, and in PET-CT, if elected.
    • There is one month elective time and approximately one day per week of allotted “academic time” to pursue research interests.
    • The fellowship runs from July 1 to June 30.
    Eligibility

    U.S. applicants must be board eligible or board certified in radiology. Foreign applicants must be ECFMG certified, trained in radiology and eligible to obtain a clinical visa prior to starting the fellowship. The fellowship at Dana-Farber is structured in accordance with fellowship regulations as provided by the Department of Radiology at BWH.

    Application procedure

    Applicants should send their C.V. and three reference letters (sent directly by the referees) to:

    Fiona M. Fennessy, MD, PhD, Cancer Imaging Fellowship Program Director
    Katherine M. Krajewski, MD, Associate Program Director
    Dana-Farber Cancer Institute, Department of Imaging (DL101)
    450 Brookline Avenue
    Boston, MA 02215
    Attention: Ellen Rolfsen

    Phone: 617-632-4891
    Fax: 617-582-8574
    Email: ellen_rolfsen@dfci.harvard.edu 

    Translational Cancer Imaging Clinical Fellowship

    The Translational Cancer Imaging Fellowship is designed to teach trainees how imaging is being used in the context of the progress made in molecular medicine. Trainees will gain expertise in the understanding of the molecular mechanisms of cancer, the molecular-targeted drugs used to treat it, and the multiparametric anatomic and functional imaging tools available to diagnose cancer and evaluate responses to treatment.

    Particular emphasis is placed on the use of imaging as a biomarker of response to treatment, the use and interpretation of tumor metrics, the comparative effectiveness of imaging procedures, the quantitation of imaging results and the validation of imaging analysis methods.

    Rotation overview
    • Four months in nuclear medicine, including training in general nuclear medicine, cardiac imaging, PET/CT with FDG, as well as novel PET tracers of cell proliferation, hypoxia, and apoptosis.
    • Four months in cross-sectional imaging, including advanced applications with 64-slice CT, and 3T MRI.
    • Four months in the design and implementation of a clinical trial that includes imaging as a primary endpoint. The trainee will learn to oversee all aspects of a clinical trial, which includes: concept development, protocol writing, protocol submission for institutional review board (IRB) approval, participant recruitment, informed consent, data collection, analysis, interpretation, and presentation of these data.
    • The fellowship runs from July 1 to June 30.
    Eligibility

    U.S. applicants must be board eligible or board certified in radiology. Foreign applicants must be ECFMG certified, trained in radiology and eligible to obtain a clinical visa prior to starting the fellowship. The fellowship at Dana-Farber is structured in accordance with the fellowship regulations as provided by the Department of Radiology at BWH and the BWH GME office.

    Application procedure

    Applicants should send C.V. and three reference letters (sent directly by the referees) to:

    Annick D. Van den Abbeele, MD, Chief Department of Imaging
    Dana-Farber Cancer Institute
    Department of Imaging
    450 Brookline Avenue
    Boston MA 02215
    Attention: Ellen Rolfsen

    Phone: 617-632-4891
    Fax: 617-582-8574
    Email: ellen_rolfsen@dfci.harvard.edu 

    Nuclear Oncology/PET-CT Clinical Fellowship

    Dana-Farber Cancer Institute/Brigham and Women's Hospital, Nuclear Medicine Oncology Program is accepting applications from MD/MD-PhD affiliates for a one-year Nuclear Oncology/PET-CT Fellowship with the opportunity to extend to a second year.

    Dana-Farber Cancer Institute is designated a comprehensive cancer center by the National Cancer Institute. The clinical fellowship will provide physicians with advanced clinical imaging training in oncology with a focus on PET/CT and cross-sectional imaging. Fellows also have the opportunity to participate in various clinical research projects. Major areas of interest include molecular imaging, evaluation of molecularly-targeted drugs, and new PET radiopharmaceuticals. The clinical research practice is supported by a tumor metrics core laboratory for local, national, and global trials. Dana-Farber Cancer Institute is an affiliate of the Harvard Medical School Joint Program in Nuclear Medicine.

    Eligibility

    Completion of the USMLE parts I, II, and III, and American Board of Radiology (ABR) and/or American Board of Nuclear Medicine (ABNM) eligible or certified.

    Application procedure

    Interested applicants should send a letter of intent, their C.V., and the names of three contacts for references or three reference letters to:

    Fiona M. Fennessy, MD, PhD, Cancer Imaging Fellowship Program Director
    Katherine M. Krajewski, MD Associate Program Director
    Dana-Farber Cancer Institute, Department of Imaging (DL101)
    450 Brookline Ave.
    Boston, MA 02115
    Attention: Ellen Rolfsen

    Phone: 617-632-4891
    Fax: 617-582-8574
    Email: ellen_rolfsen@dfci.harvard.edu 

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms